The success of GLP-1R-targeting drugs highlights their viability as a treatment approach. Currently, there are four ...

Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share ...

The stocks of companies that make the new class of drugs to treat obesity and manage diabetes were higher across the board ...

Mounjaro is a treatment for Type 2 diabetes that activates GIP and GLP-1 pathways to help regulate blood sugar. It’s part of ...

Shares of Eli Lilly LLY and Novo Nordisk NVO were up on Tuesday, likely due to a proposal by President Biden that Medicare ...

Pharmaceutical stocks make great additions to any portfolio in any market environment. A good one promises steady revenue ...

It’s unclear what impact a change in presidential administration will have on the proposal to widen access for those with obesity.

That increased convenience will have to be accompanied by weight loss that is at least as effective as its rivals, and Amgen ...

Share on Facebook Share on Twitter Under a new rule the Biden administration proposed on Tuesday, millions of Americans with ...

Outgoing US President Joe Biden proposed Tuesday to give millions more Americans access to weight loss drugs -- but Donald ...

President-elect Donald Trump, a Biden administration proposal would require Medicare and Medicaid to cover weight-loss drugs ...

Amgen's MariTide shows promising weight loss results in Phase II for type 2 diabetes. Find out why AMGN stock remains as a strong buy for long-term investors.